We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF

142 hedge funds and large institutions have $514M invested in VanEck Pharmaceutical ETF in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 47 increasing their positions, 41 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more capital inflows, than outflows

Capital inflows: $123M | Capital outflows: $101M

15% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 41

12.32% more ownership

Funds ownership: 75.2% → 87.52% (+12%)

0% more funds holding

Funds holding: 142 → 142 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 27

71% less call options, than puts

Call options by funds: $1.25M | Put options by funds: $4.37M

Holders
142
Holders Change
–
Holders Change %
0%
% of All Funds
1.86%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
23
Increased
47
Reduced
41
Closed
27
Calls
$1.25​M
Puts
$4.37​M
Net Calls
-⁠$3.12​M
Net Calls Change
-⁠$3.62​M

PPH Hedge Fund Activity: Q4 2024 in Review

142 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2024, worth a combined $514M — down 5.2% from $542M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of PPH and 23 opened new positions — a net loss of 4 holders — while 41 trimmed existing stakes and 47 added.

The largest buyer was Goldman Sachs, adding an estimated $17.6M. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $23.6M sold.

  • 142 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $514M of VanEck Pharmaceutical ETF stock for Q4 2024, down 5.2% quarter-over-quarter.
  • 23 funds opened new VanEck Pharmaceutical ETF positions in Q4 2024 and 27 closed out, a net change of -4 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2024 was Goldman Sachs, an estimated $17.6M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2024 was Mirae Asset Global Investments, an estimated $23.6M sold.

Based on aggregated 13F filings for Q4 2024.